Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
HYPERFRACTIONATED ACCELERATED RADIATION-THERAPY FOR NONSMALL CELL LUNG-CANCER - CLINICAL-PHASE I II TRIAL/
Autore:
FU XL; JIANG GL; WANG LJ; QIAN H; FU S; YIE M; KONG FM; ZHAO S; HE SQ; LIU TF;
Indirizzi:
SHANGHAI MED UNIV,CANC HOSP,DEPT RADIAT ONCOL,399 LING LING RD SHANGHAI 200032 PEOPLES R CHINA SHANGHAI MED UNIV,CANC HOSP,DEPT RADIAT ONCOL SHANGHAI 200032 PEOPLESR CHINA
Titolo Testata:
International journal of radiation oncology, biology, physics
fascicolo: 3, volume: 39, anno: 1997,
pagine: 545 - 552
SICI:
0360-3016(1997)39:3<545:HARFNC>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
EXPERIENCE; RADIOTHERAPY; CARCINOMA; CHART;
Keywords:
NONSMALL CELL LUNG CANCER; ACCELERATED PROLIFERATION; RADIOTHERAPY; HYPERFRACTIONATED IRRADIATION; ACCELERATED IRRADIATION; HYPERFRACTIONATED ACCELERATED IRRADIATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
9
Recensione:
Indirizzi per estratti:
Citazione:
X.L. Fu et al., "HYPERFRACTIONATED ACCELERATED RADIATION-THERAPY FOR NONSMALL CELL LUNG-CANCER - CLINICAL-PHASE I II TRIAL/", International journal of radiation oncology, biology, physics, 39(3), 1997, pp. 545-552

Abstract

Purpose: In an attempt to improve local control and survival of nonsmall cell lung cancer (NSCLC),hyperfractionated accelerated radiation therapy (HART) was carried out as a clinical phase I/II trial. Methods and Materials: HART was delivered by 1.1 Gy/fraction, three fractions per day with intervals of 4 h and five treatment days per week. The clinical tumors were irradiated to 74.3 Gy (72.6-75.9)/66-69 fx, 33 days(29-40) (not corrected for lung density), and the subclinical lesions, to 50.0 Gy (48.4-50.6)/44-46 fx, 33 days (29-40). Sixty-nine patients with NSCLC were enrolled in this study. Nine patients were withdrawnfrom the study during HART due to different reasons. Sixty patients formed the study for outcome analyses. They were 57 males and 3 femaleswith median age of 61 years (21-77). There were 41 cases of squamous cell carcinoma, 15 cases of adenocarcinoma, and 4 cases of large cell carcinoma. Overall, favorable patients (KPS greater than or equal to 70, weight loss <5% and Stages I, II, IIIa) accounted for 73% (44 of 60) of all patients. Forty-four patients (73%) received adjuvant chemotherapy (DDP + VP16) with median cycles of 1.8 before and/or after HART. In order to compare the outcome of HART with conventional irradiation, 50 NSCLC patients treated by conventional fractionated irradiation (CFI) during the same period were chosen as the basis to evaluate relative effects of HART. They derived from the control group of another clinical trial of hyperfractionated irradiation for NSCLC in the same department. They received median tumor dose of 63.9 Gy (62.8-65.0)/34 fx(32-36), 48 days (45-53). Results: 1. Acute and late complications: (a) In HART, 87% of patients (52 cases) developed acute radiation esophagitis: Grade 1-2, 46 cases (77%) and Grade 3, 6 cases (10%), at 2.5 weeks (2-3.5 weeks) after HART began. Five patients with Grade 3 esophagitis had their HART interrupted for less than or equal to 7 days. In CFI, esophagitis was much less (44%, p < 0.05) with 38% of Grade 1-2 and 6% of Grade 3. (b) In HART, acute pulmonary symptoms (RTOG Grade 1-2) occurred in 17% (10 cases), and acute radiation pneumonitis (Grade 3), in 8% (5 cases), while in CFI, they were 24% and 2% (p > 0.05), respectively. Late lung fibrosis (RTOG Grade 1-2) appeared in 20% (12 cases), whereas 18% in CFI (p > 0.05). (c), No other severe acute or late complications have been observed so far in HART. 2. Immediate response. In HART, 20% of patients (12 cases) achieved CR, 60% (36 cases), PR and 20% (12 cases), NR or PD. In CFI, the above three percentages were 10, 28, and 62%, respectively (p < 0.001). 3. Follow-up. The 1-, 2-, and 3-year actuarial survivals were 72, 47, and 28% for HART, and 60, 18, and 6% for CFI, respectively (p < 0.001). Better local control was seen in HART than in CFI with 1-, 2-, and 3-year local control rates being 71, 44, 29%, and 60, 20, and 5%, respectively (p = 0.001). Distant metastases developed less in HART than in CFI. The 1-, 2-, and 3-year distant metastasis rates were 23, 36, and 50% in HART, but 30, 48, and 80% in CFI (p = 0.021). Conclusion: 1. HART could be tolerated by most of the favorable NSCLC patients. The predominant complication was acute esophagitis. No other severe acute or late complications havebeen observed so far. 2. HART resulted in better survivals and local controls, and less distant metastases than CFI. (C) 1997 Elsevier Science Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 07:43:35